Latest Articles
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Yahoo Finance
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Yahoo Finance
Published: Oct. 18, 2025, 10 a.m.
AKR1B1 and AKR1B10 as prognostic markers in endometrial cancer - BioWorld MedTech
AKR1B1 and AKR1B10 as prognostic markers in endometrial cancer BioWorld MedTech
Published: Oct. 17, 2025, 1 p.m.
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots
Published: Oct. 16, 2025, 10 a.m.
Circulating biomarkers of infection and endometrial cancer risk - springermedicine.com
Circulating biomarkers of infection and endometrial cancer risk springermedicine.com
Published: Oct. 16, 2025, 2:26 a.m.
Dr Pillay: Endometrial cancer on the rise - The Fiji Times
Dr Pillay: Endometrial cancer on the rise The Fiji Times
Published: Oct. 16, 2025, 12:31 a.m.
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer - OncLive
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer OncLive
Published: Oct. 15, 2025, 5:46 p.m.
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer - OncLive
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer OncLive
Published: Oct. 15, 2025, 12:10 p.m.
Endometrial Cancer Treatment Market Forecast to Reach USD 53.7 Billion by 2035, Driven by Innovation and Expanding Access to Care – FMIBlog - FMIBlog
Endometrial Cancer Treatment Market Forecast to Reach USD 53.7 Billion by 2035, Driven by Innovation and Expanding Access to Care – FMIBlog FMIBlog
Published: Oct. 15, 2025, 6:44 a.m.
Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com
Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer geneonline.com
Published: Oct. 14, 2025, 6:39 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org
Published: Oct. 14, 2025, 4:49 p.m.
Link copied to clipboard!